The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis. Mavyret is also approved for adult patients with HCV genotype...
Tag: <span>Hepatitis C</span>
Post
No evidence that $40,000 ‘miracle’ drug cures hepatitis C, report finds
There is no valid evidence that direct-acting antiviral drugs cure hepatitis C The drug was hailed as a ‘miracle’ after it was able to rid the blood of the virus A report claims despite the $40,000 drug the disease can still linger in the body The virus is now the United States’ most common blood-borne infection...
Post
New Drug Reduces Transplant and Mortality Rates Significantly in Patients with Hepatitis C, Study Finds
Patients with hepatitis C who suffer from advanced stages of liver disease have renewed hope, thanks to findings by researchers who have discovered that a new drug significantly reduces their risk of death and need for transplantation. The research team, led by clinical researchers at Intermountain Healthcare’s Intermountain Medical Center in Salt Lake City,...